Sagimet Biosciences (SGMT) files Form 3 identifying Chief Medical Officer Andreas Grauer

Rhea-AI Filing Summary

Sagimet Biosciences Inc. filed a Form 3 insider report for Andreas Grauer, who is identified as the company’s Chief Medical Officer. The filing does not list any securities transactions or derivative positions, and no share holdings are detailed in the provided data.

Key Terms

Chief Medical Officer, Form 3, insider filing

3 terms

Chief Medical Officer financial

"officer_title: "Chief Medical Officer""

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

insider filing regulatory

"INSIDER FILING DATA (Form 3): {"

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Grauer Andreas

(Last) (First) (Middle)

SAGIMET BIOSCIENCES INC.

155 BOVET ROAD, SUITE 303

(Street)

SAN MATEO CALIFORNIA 94402

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/20/2026

3. Issuer Name and Ticker or Trading Symbol
Sagimet Biosciences Inc. [ SGMT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Elizabeth Rozek, Attorney-in-Fact	05/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the Sagimet Biosciences (SGMT) Form 3 for Andreas Grauer show?

The Form 3 for Sagimet Biosciences (SGMT) lists Andreas Grauer as Chief Medical Officer. It provides insider identification but, in the provided data, does not report any securities transactions, derivative positions, or specific share holdings for him.

Who is the reporting person on Sagimet Biosciences (SGMT) Form 3?

The reporting person on the Sagimet Biosciences (SGMT) Form 3 is Andreas Grauer. He is identified as an officer of the company and serves in the role of Chief Medical Officer according to the filing data.

Does the Sagimet Biosciences (SGMT) Form 3 for Andreas Grauer show any insider trades?

No insider trades are shown for Andreas Grauer in the Sagimet Biosciences (SGMT) Form 3. The transaction section is empty, with zero buy, sell, exercise, gift, tax withholding, or restructuring transactions reported in the summarized data.

Are any share or option holdings disclosed for Andreas Grauer in SGMT’s Form 3?

The summarized Form 3 data for Sagimet Biosciences (SGMT) does not disclose any specific share or option holdings for Andreas Grauer. Both the transactions list and the derivative positions summary are empty in the provided information.

What officer role does Andreas Grauer hold at Sagimet Biosciences (SGMT)?

According to the Form 3 filing data, Andreas Grauer is an officer of Sagimet Biosciences (SGMT). His listed officer title in the filing is Chief Medical Officer, indicating executive responsibility for the company’s medical and clinical functions.